The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Quadruplet regimens and antibodies for newly diagnosed multiple myeloma
Moving forward in the US from standard triplet regimens for the frontline treatment of transplant-ineligible, Noopur Raje, MD, from Massachusetts General Hospital, Boston, MA, discusses quadruplet protocols and the addition of antibodies to treatment regimens. Dr Raje covers the TOURMALINE-MM2 study (NCT01850524), which added ixazomib to lenalidomide-dexamethasone, and future plans to add an antibody to this regimen. She also highights two other studies which have incorporated daratumumab (MAIA; NCT02252172) and elotuzumab. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
